CARA

Oral Korsuva

Pruritus CKD 3-5

Stage (next event)

Expected Date

Phase 3 TBA

H2 2020

Catalyst Info & Data Links

TITLE: Oral Korsuva in Pruritus CKD 3-5


WHAT IS THE CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA/EVENTS


PRESS RELEASE

POSTERS


PRESENTATIONS

PUBLICATIONS

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • Difelikefalin (CR845) is a peripherally restricted, selective kappa opioid receptor agonist that exerts antipruritic effects by means of activation of kappa opioid receptors on peripheral neurons and immune cells. The hydrophilic small-peptide structure restricts passive diffusion across membranes, thereby limiting access to kappa opioid receptors in the central nervous system (Fishbane et al., 2020).

COMPETITORS

MARKET

  • ~7.3 million diagnosed with CKD (IQVIA est)


Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

CARA Reports Success in Kidney Disease Itching

Amp Core Q2 '19 Report

Amp Mid-Q1 '19 Update

CARA Mid-Q1 '19 Update

Cara Therapeutics - Itching For Big Returns In 2019

Amp Up July 2018

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon